Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3158649 | 0.95 | HTR2C (0.50) | HTR2CGID4HTR2AHTR2BDRD2 | |
| SCHEMBL6558765 | 0.79 | HTR2C (0.45) | HTR2CHTR2AHTR2BDRD2MEN1 | |
| SCHEMBL4984697 | 0.77 | ADRA2A (0.38) | ALDH1A1KDM4EMEN1NPC1GAA | |
| SCHEMBL7844832 | 0.76 | HTR2C (0.72) | HTR2CGID4HTR2AHTR2BDRD2 | |
| SCHEMBL2218295 | 0.76 | HTR2C (0.54) | HTR2CHTR2AHTR2BADRA1ADDB1 | |
| SCHEMBL3159426 | 0.76 | TAAR1 (0.46) | HTR2CHTR2AHTR2BKDM1ARCOR1 | |
| SCHEMBL2095198 | 0.75 | HTR2C (0.70) | HTR2CGID4HTR2AHTR2BDRD2 | |
| Ammonia Solution, Strong SCHEMBL19664329 | 0.75 | HTR2C (0.70) | HTR2CGID4HTR2AHTR2BDRD2 | |
| SCHEMBL186274 | 0.74 | NOS1 (0.52) | HTR2CADRA1AALDH1A1KDM1ARCOR1 | |
| SCHEMBL3169257 | 0.73 | HTR2C (0.46) | HTR2CHTR2AHTR2BDRD2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396316-B1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | claimed |
| US-8937078-B2 | Quinazolinones as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | claimed |
| EP-2396316-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2011-12-21 | — | — | EP | claimed |
| WO-2010093727-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-19 | — | — | WO | claimed |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | claimed |
| US-6596724-B2 | Used in promoting weight loss and treating eating disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | claimed |
| US-6391881-B2 | ANOREXOGENIC AGENTS TO PROMOTE WEIGHT LOSS AND TREAT EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-21 | — | — | US | claimed |
| US-20020013323-A1 | Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-31 | — | — | US | claimed |
| WO-2001089528-A1 | THIOUREA DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-29 | — | — | WO | claimed |
| US-20010047003-A1 | Anorexogenic agents to promote weight loss and treat eating disorders | SIT SING-YUEN (US) | 2001-11-29 | — | — | US | claimed |
| US-9458120-B2 | Phenoxypropanol derivative and pharmaceutical composition including the same | KORBA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-10-04 | — | — | US | disclosed |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2016-01-21 | — | — | US | disclosed |
| EP-2396316-B1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | disclosed |
| US-20150166496-A1 | DERIVATIVES OF 1-PHENOXY PROPAN-2-OL AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-06-18 | — | — | US | disclosed |
| US-8937078-B2 | Quinazolinones as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | HTR2C 2479/4885GID4 744/4885HTR2A 2872/4885 |
| US-20150166496-A1 | DERIVATIVES OF 1-PHENOXY PROPAN-2-OL AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CACNA1G, CACNA1H, CACNA1I | HTR2C 1104/4885GID4 2268/4885HTR2A 817/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | HTR2C 773/4885GID4 3320/4885HTR2A 1246/4885 |
| US-20020013323-A1 | Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists | NPY1R, NPY2R, NPY5R | HTR2C 146/4885GID4 409/4885HTR2A 252/4885 |
| US-20010047003-A1 | Anorexogenic agents to promote weight loss and treat eating disorders | NPY1R, NPY2R, NPY5R | HTR2C 102/4885GID4 318/4885HTR2A 106/4885 |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | HIF1AN, CXCL12, HIF1A | HTR2C 4874/4885GID4 1480/4885HTR2A 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.